Review



lenticrispr v2 expression constructs  (Addgene inc)


Bioz Verified Symbol Addgene inc is a verified supplier  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 96
      Buy from Supplier

    Structured Review

    Addgene inc lenticrispr v2 expression constructs
    Lenticrispr V2 Expression Constructs, supplied by Addgene inc, used in various techniques. Bioz Stars score: 96/100, based on 5740 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/lenticrispr+v2+expression+constructs/pmc12205516-46-8-16?v=Addgene+inc
    Average 96 stars, based on 5740 article reviews
    lenticrispr v2 expression constructs - by Bioz Stars, 2026-07
    96/100 stars

    Images



    Similar Products

    lenticrispr v2 expression constructs  (Addgene inc)
    96
    Addgene inc lenticrispr v2 expression constructs
    Lenticrispr V2 Expression Constructs, supplied by Addgene inc, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/lenticrispr+v2+expression+constructs/pmc12205516-46-8-16?v=Addgene+inc
    Average 96 stars, based on 1 article reviews
    lenticrispr v2 expression constructs - by Bioz Stars, 2026-07
    96/100 stars
    		  Buy from Supplier
    construct expressing sgrna  (Addgene inc)
    96
    Addgene inc construct expressing sgrna
    Construct Expressing Sgrna, supplied by Addgene inc, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/lenticrispr+v2+expression+constructs/pm35779634-215-7-15?v=Addgene+inc
    Average 96 stars, based on 1 article reviews
    construct expressing sgrna - by Bioz Stars, 2026-07
    96/100 stars
    		  Buy from Supplier
    cas9 expression construct lenticrispr v2  (Addgene inc)
    96
    Addgene inc cas9 expression construct lenticrispr v2
    ( A ) The expression of PD-1H on activated WT OT-I cells was analyzed by flow cytometry. ( B ) CFSE-labeled EG7 or B16-OVA tumor cells were coincubated with activated PKO or WT OT-I cells at the different effector/target (E:T) ratios for 4 hours. Cells were stained with DAPI and analyzed by flow cytometry. Data are representative of 3 independent experiments with mean ± SEM. * P < 0.05, *** P < 0.001, and **** P < 0.0001 (2-way ANOVA). ( C ) <t>CRISPR/Cas9</t> efficiently disrupted the expression of PD-1H on CD8 + T cells. PD-1H expression was analyzed in the GFP + gate by flow cytometry. ( D ) The killing activity of sgRNA OT-I cells on EG7 cells in vitro was analyzed by CFSE/DAPI staining. EG7-bearing mice ( n = 4 for the control group; n = 5 per group) received an i.v. injection of OT-I cells or PBS. ( E ) Tumor growth was monitored from day 6, and tumor weight at day 16 is shown. NC, negative control; Ctrl, control. Data are representative of 2 independent experiments with mean ± SEM. P values by 2-tailed unpaired t test (right graph in E ) and 2-way ANOVA (left graph in E ). * P < 0.05; ** P < 0.01; *** P < 0.001; **** P < 0.0001.
    Cas9 Expression Construct Lenticrispr V2, supplied by Addgene inc, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/lenticrispr+v2+expression+constructs/pmc08855794-190-1-6?v=Addgene+inc
    Average 96 stars, based on 1 article reviews
    cas9 expression construct lenticrispr v2 - by Bioz Stars, 2026-07
    96/100 stars
    		  Buy from Supplier
    sgrnas expression constructs  (Addgene inc)
    96
    Addgene inc sgrnas expression constructs
    ( A ) The expression of PD-1H on activated WT OT-I cells was analyzed by flow cytometry. ( B ) CFSE-labeled EG7 or B16-OVA tumor cells were coincubated with activated PKO or WT OT-I cells at the different effector/target (E:T) ratios for 4 hours. Cells were stained with DAPI and analyzed by flow cytometry. Data are representative of 3 independent experiments with mean ± SEM. * P < 0.05, *** P < 0.001, and **** P < 0.0001 (2-way ANOVA). ( C ) <t>CRISPR/Cas9</t> efficiently disrupted the expression of PD-1H on CD8 + T cells. PD-1H expression was analyzed in the GFP + gate by flow cytometry. ( D ) The killing activity of sgRNA OT-I cells on EG7 cells in vitro was analyzed by CFSE/DAPI staining. EG7-bearing mice ( n = 4 for the control group; n = 5 per group) received an i.v. injection of OT-I cells or PBS. ( E ) Tumor growth was monitored from day 6, and tumor weight at day 16 is shown. NC, negative control; Ctrl, control. Data are representative of 2 independent experiments with mean ± SEM. P values by 2-tailed unpaired t test (right graph in E ) and 2-way ANOVA (left graph in E ). * P < 0.05; ** P < 0.01; *** P < 0.001; **** P < 0.0001.
    Sgrnas Expression Constructs, supplied by Addgene inc, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/lenticrispr+v2+expression+constructs/pm32142663-134-48-64?v=Addgene+inc
    Average 96 stars, based on 1 article reviews
    sgrnas expression constructs - by Bioz Stars, 2026-07
    96/100 stars
    		  Buy from Supplier
    lentivirus expressing plenticrisprv2 constructs  (Addgene inc)
    96
    Addgene inc lentivirus expressing plenticrisprv2 constructs
    ( A ) The expression of PD-1H on activated WT OT-I cells was analyzed by flow cytometry. ( B ) CFSE-labeled EG7 or B16-OVA tumor cells were coincubated with activated PKO or WT OT-I cells at the different effector/target (E:T) ratios for 4 hours. Cells were stained with DAPI and analyzed by flow cytometry. Data are representative of 3 independent experiments with mean ± SEM. * P < 0.05, *** P < 0.001, and **** P < 0.0001 (2-way ANOVA). ( C ) <t>CRISPR/Cas9</t> efficiently disrupted the expression of PD-1H on CD8 + T cells. PD-1H expression was analyzed in the GFP + gate by flow cytometry. ( D ) The killing activity of sgRNA OT-I cells on EG7 cells in vitro was analyzed by CFSE/DAPI staining. EG7-bearing mice ( n = 4 for the control group; n = 5 per group) received an i.v. injection of OT-I cells or PBS. ( E ) Tumor growth was monitored from day 6, and tumor weight at day 16 is shown. NC, negative control; Ctrl, control. Data are representative of 2 independent experiments with mean ± SEM. P values by 2-tailed unpaired t test (right graph in E ) and 2-way ANOVA (left graph in E ). * P < 0.05; ** P < 0.01; *** P < 0.001; **** P < 0.0001.
    Lentivirus Expressing Plenticrisprv2 Constructs, supplied by Addgene inc, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/lenticrispr+v2+expression+constructs/pmc05444426__atv___37___1115___s002-16-8-12?v=Addgene+inc
    Average 96 stars, based on 1 article reviews
    lentivirus expressing plenticrisprv2 constructs - by Bioz Stars, 2026-07
    96/100 stars
    		  Buy from Supplier

    Image Search Results


    ( A ) The expression of PD-1H on activated WT OT-I cells was analyzed by flow cytometry. ( B ) CFSE-labeled EG7 or B16-OVA tumor cells were coincubated with activated PKO or WT OT-I cells at the different effector/target (E:T) ratios for 4 hours. Cells were stained with DAPI and analyzed by flow cytometry. Data are representative of 3 independent experiments with mean ± SEM. * P < 0.05, *** P < 0.001, and **** P < 0.0001 (2-way ANOVA). ( C ) CRISPR/Cas9 efficiently disrupted the expression of PD-1H on CD8 + T cells. PD-1H expression was analyzed in the GFP + gate by flow cytometry. ( D ) The killing activity of sgRNA OT-I cells on EG7 cells in vitro was analyzed by CFSE/DAPI staining. EG7-bearing mice ( n = 4 for the control group; n = 5 per group) received an i.v. injection of OT-I cells or PBS. ( E ) Tumor growth was monitored from day 6, and tumor weight at day 16 is shown. NC, negative control; Ctrl, control. Data are representative of 2 independent experiments with mean ± SEM. P values by 2-tailed unpaired t test (right graph in E ) and 2-way ANOVA (left graph in E ). * P < 0.05; ** P < 0.01; *** P < 0.001; **** P < 0.0001.

    Journal: JCI Insight

    Article Title: Ablation of T cell–associated PD-1H enhances functionality and promotes adoptive immunotherapy

    doi: 10.1172/jci.insight.148247

    Figure Lengend Snippet: ( A ) The expression of PD-1H on activated WT OT-I cells was analyzed by flow cytometry. ( B ) CFSE-labeled EG7 or B16-OVA tumor cells were coincubated with activated PKO or WT OT-I cells at the different effector/target (E:T) ratios for 4 hours. Cells were stained with DAPI and analyzed by flow cytometry. Data are representative of 3 independent experiments with mean ± SEM. * P < 0.05, *** P < 0.001, and **** P < 0.0001 (2-way ANOVA). ( C ) CRISPR/Cas9 efficiently disrupted the expression of PD-1H on CD8 + T cells. PD-1H expression was analyzed in the GFP + gate by flow cytometry. ( D ) The killing activity of sgRNA OT-I cells on EG7 cells in vitro was analyzed by CFSE/DAPI staining. EG7-bearing mice ( n = 4 for the control group; n = 5 per group) received an i.v. injection of OT-I cells or PBS. ( E ) Tumor growth was monitored from day 6, and tumor weight at day 16 is shown. NC, negative control; Ctrl, control. Data are representative of 2 independent experiments with mean ± SEM. P values by 2-tailed unpaired t test (right graph in E ) and 2-way ANOVA (left graph in E ). * P < 0.05; ** P < 0.01; *** P < 0.001; **** P < 0.0001.

    Article Snippet: The Cas9 expression construct LentiCRISPR v2 (Addgene 52961) was modified by adding an GFP sequence to replace the puro sequence (LentiCRISPR-GFP).

    Techniques: Expressing, Flow Cytometry, Labeling, Staining, CRISPR, Activity Assay, In Vitro, Control, Injection, Negative Control